Transaction DateRecipientSharesTypePriceValue
22nd September 2020Advisors Llc Perceptive1,644,785Conversion of derivative$0.00
22nd September 2020Advisors Llc Perceptive1,058,824Open or private purchase$17.00$18,000,008.00
15th September 2020Advisors Llc Perceptive2,911,764Open or private purchase$4.25$12,374,997.00
14th September 2020Advisors Llc Perceptive1,800,000Open or private purchase$11.00$19,800,000.00
14th September 2020Advisors Llc Perceptive400,000Open or private purchase$40.00$16,000,000.00
11th September 2020Martha J Demski2,200Open or private purchase$2.29$5,038.00
10th September 2020Advisors Llc Perceptive200,000Open or private purchase$11.24$2,248,000.00
10th September 2020Jerrold B Grossman5,000Open or private purchase$2.22$11,100.00
8th September 2020Adam S Grossman4,000Open or private purchase$2.24$8,959.60
8th September 2020James Mond4,000Open or private purchase$2.20$8,800.00
Adma Biologics
Adma Biologics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 0/10.


ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center and Corporate.


Ticker: ADMA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1368514
Employees: 318
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Common Stock, Shares, Issued: $86 M (45%)